ENTA DB webcast disclosure: ENTA can earn $80M in pre-commercial regulatory milestones from ABBV for ABT-493 (ENTA’s next-gen pan-genotypic PI); this is separate from the $195M in regulatory milestones ENTA can earn from ABBV on ABT-450.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”